{"gene":"ARRDC1","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":2013,"finding":"ARRDC1 (α-arrestin 1) heterodimerizes with β-arrestins and uses its PPxY motifs to directly bind the Itch E3 ubiquitin ligase, forming a tripartite complex that promotes Itch-mediated ubiquitylation and lysosomal degradation of non-activated Notch receptor; mutation of ARRDC1 PPxY motifs reduces Notch ubiquitylation and impairs lysosomal degradation.","method":"Co-immunoprecipitation, PPxY mutant transfection, ubiquitylation assays, lysosomal degradation assays in β-arrestin-/- and Itch-/- cells","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, mutagenesis of PPxY motifs, genetic validation in knockout cell lines, multiple orthogonal methods in one study","pmids":["23886940"],"is_preprint":false},{"year":2018,"finding":"ARRDC1 interacts with YAP1 via its PPXY motifs (binding the WW domains of YAP1) and facilitates Itch E3 ubiquitin ligase-mediated ubiquitination and proteasomal/lysosomal degradation of YAP1, thereby negatively regulating YAP1 protein stability and suppressing renal cell carcinoma cell growth, migration, invasion, and EMT.","method":"Tandem affinity purification/mass spectrometry, co-immunoprecipitation, lentiviral shRNA knockdown, functional cell assays (proliferation, migration, invasion, EMT)","journal":"American journal of cancer research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, AP-MS interaction discovery, domain mapping (PPXY/WW), functional rescue with multiple orthogonal assays, single lab","pmids":["29416926"],"is_preprint":false},{"year":2018,"finding":"ARRDC1 regulates the release of both exosomes and ectosomes (extracellular vesicles) and controls their protein cargo; deletion of Arrdc1 in mouse embryonic fibroblasts alters EV protein composition, including enrichment of mitochondrial proteins in ectosomes and depletion of apoptotic cleavage/cornified envelope proteins in exosomes.","method":"Arrdc1-/- mouse embryonic fibroblasts, nanoparticle tracking analysis, proteomic analysis of isolated EVs","journal":"Proteomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with quantitative EV analysis and proteomics, single lab, two orthogonal methods","pmids":["30035390"],"is_preprint":false},{"year":2025,"finding":"ARRDC1 restricts Semliki Forest virus (alphavirus) replication by binding to viral nonstructural protein 4 (nsP4) and facilitating its ubiquitination-dependent degradation; this antiviral function requires ARRDC1's plasma membrane localization and its ubiquitin ligase binding motif (PPxY).","method":"siRNA knockdown, CRISPR/Cas9 knockout, trans-complementation, Co-immunoprecipitation (ARRDC1–nsP4 interaction), viral replication assays, PPxY motif mutant analysis","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic KO/KD plus trans-complementation, Co-IP of viral substrate, domain/motif mutant validation, multiple orthogonal methods in one study","pmids":["40824091"],"is_preprint":false},{"year":2024,"finding":"Fusion of ARRDC1 to p53 (ARRDC1-p53) substantially increases loading of p53 fusion protein and its mRNA into small extracellular vesicles (sEVs), demonstrating that ARRDC1 serves as an active cargo-loading mechanism for sEV biogenesis; overexpression of ARRDC1 also boosts sEV production (elevated TSG101 and LAMP1).","method":"Overexpression of ARRDC1-p53 fusion constructs in HEK293T, Western blot for sEV markers, functional apoptosis/proliferation assays in recipient cells","journal":"Biomolecules","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — overexpression fusion strategy with functional readout, multiple cell assays, single lab","pmids":["38785998"],"is_preprint":false},{"year":2025,"finding":"Engineered ARRDC1-mediated microvesicles (ARMMs) can be loaded with protein, mRNA, or CRISPR-Cas9 cargo and deliver them intracellularly; surface decoration with cell-targeting ligands enables selective delivery to CD8+ T cells or parvalbumin-positive neurons in vivo, demonstrating that ARRDC1's membrane budding activity can be harnessed for programmable intracellular cargo delivery.","method":"Engineered ARMM production with targeted surface proteins, in vitro and in vivo delivery assays, functional gene editing readouts","journal":"Journal of extracellular vesicles","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo functional delivery with multiple cargo types, single lab, engineering study rather than pure mechanistic dissection","pmids":["41392542"],"is_preprint":false}],"current_model":"ARRDC1 is a plasma membrane-localized α-arrestin adaptor protein that uses its PPxY motifs to recruit the Itch E3 ubiquitin ligase and cooperates with β-arrestins to drive ubiquitination and lysosomal/proteasomal degradation of substrates including Notch and YAP1; it also controls the biogenesis and protein cargo of extracellular vesicles (both exosomes and ectosomes), and its ubiquitin ligase-binding activity and membrane localization enable an antiviral function through ubiquitin-mediated degradation of alphavirus nsP4."},"narrative":{"mechanistic_narrative":"ARRDC1 is a plasma membrane α-arrestin adaptor that couples substrate recognition to ubiquitin-mediated turnover and drives the budding of extracellular vesicles [PMID:23886940, PMID:30035390]. It heterodimerizes with β-arrestins and uses its PPxY motifs to directly recruit the Itch E3 ubiquitin ligase, forming a tripartite complex that ubiquitylates substrates and routes them to lysosomal/proteasomal degradation; mutation of the PPxY motifs abolishes this activity [PMID:23886940]. Through this PPxY/Itch axis it promotes degradation of non-activated Notch [PMID:23886940] and binds the WW domains of YAP1 to control YAP1 protein stability, with loss of ARRDC1-driven YAP1 turnover relieving suppression of renal cell carcinoma growth, migration, invasion, and EMT [PMID:29416926]. Independently of its degradative role, ARRDC1 governs the biogenesis and protein cargo of both exosomes and ectosomes, and its membrane-budding activity can be redirected to actively load defined protein and nucleic-acid cargo into secreted vesicles [PMID:30035390, PMID:38785998, PMID:41392542]. The same membrane localization and ubiquitin-ligase-binding motif underlie an antiviral function: ARRDC1 binds alphavirus nonstructural protein nsP4 and promotes its ubiquitination-dependent degradation to restrict Semliki Forest virus replication [PMID:40824091].","teleology":[{"year":2013,"claim":"Established the core molecular logic of ARRDC1 as an adaptor: how could an α-arrestin direct substrate degradation? It bridges β-arrestins and the Itch E3 ligase via PPxY motifs to ubiquitylate and degrade Notch.","evidence":"Co-IP, PPxY mutant transfection, ubiquitylation and lysosomal degradation assays in β-arrestin-/- and Itch-/- cells","pmids":["23886940"],"confidence":"High","gaps":["Whether Notch is recognized directly by ARRDC1 or via β-arrestin is not resolved","Physiological contexts of Notch regulation by ARRDC1 not defined"]},{"year":2018,"claim":"Extended the adaptor model to a second substrate and a disease context: ARRDC1 binds YAP1 WW domains through its PPXY motifs and drives Itch-mediated YAP1 degradation, positioning ARRDC1 as a tumor suppressor in renal cell carcinoma.","evidence":"AP-MS, reciprocal Co-IP, PPXY/WW domain mapping, shRNA knockdown, proliferation/migration/invasion/EMT assays","pmids":["29416926"],"confidence":"High","gaps":["In vivo tumor evidence not established","Relative contribution of proteasomal vs lysosomal degradation unclear"]},{"year":2018,"claim":"Defined a degradation-independent role: how does ARRDC1 shape extracellular vesicle output? Genetic loss alters the protein cargo of both exosomes and ectosomes.","evidence":"Arrdc1-/- MEFs, nanoparticle tracking, proteomic profiling of isolated EVs","pmids":["30035390"],"confidence":"Medium","gaps":["Mechanism by which ARRDC1 selects specific cargo classes not defined","Single cell type (MEF), not confirmed across tissues"]},{"year":2024,"claim":"Demonstrated that ARRDC1 actively loads cargo into vesicles rather than passively associating: ARRDC1-p53 fusion enriches p53 protein and mRNA in small EVs and boosts sEV production.","evidence":"ARRDC1-p53 fusion overexpression in HEK293T, sEV marker Western blots, functional assays in recipient cells","pmids":["38785998"],"confidence":"Medium","gaps":["Overexpression/fusion strategy may not reflect endogenous cargo loading","Mechanism of mRNA recruitment unknown"]},{"year":2025,"claim":"Showed ARRDC1's budding activity is engineerable: ARRDC1-mediated microvesicles carrying protein, mRNA, or CRISPR-Cas9 can be surface-targeted for selective in vivo delivery.","evidence":"Engineered ARMMs with targeting ligands, in vitro and in vivo delivery and gene-editing readouts","pmids":["41392542"],"confidence":"Medium","gaps":["Engineering proof-of-concept rather than endogenous mechanism","Endogenous physiological cargo and triggers of budding not addressed"]},{"year":2025,"claim":"Connected ARRDC1's degradative adaptor function to host defense: it binds alphavirus nsP4 and promotes its ubiquitination-dependent degradation to restrict viral replication, requiring membrane localization and the PPxY motif.","evidence":"siRNA knockdown, CRISPR/Cas9 KO, trans-complementation, ARRDC1–nsP4 Co-IP, PPxY mutant analysis, viral replication assays","pmids":["40824091"],"confidence":"High","gaps":["Whether the same Itch ligase mediates nsP4 ubiquitination not shown","Breadth of antiviral activity against other viruses not defined"]},{"year":null,"claim":"How ARRDC1 selects its diverse substrates and EV cargo, and whether its degradative and vesicle-budding functions are mechanistically linked, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of ARRDC1 substrate or cargo recognition","Determinants distinguishing degradative targeting from EV cargo loading unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,1,3]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[3]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[2,4,5]}],"pathway":[{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[2,4,5]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,1,3]}],"complexes":[],"partners":["ITCH","NOTCH","YAP1","NSP4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8N5I2","full_name":"Arrestin domain-containing protein 1","aliases":["Alpha-arrestin 1"],"length_aa":433,"mass_kda":46.0,"function":"Functions as an adapter recruiting ubiquitin-protein ligases to their specific substrates (PubMed:23886940, PubMed:27462458). Through an ubiquitination-dependent mechanism plays for instance a role in the incorporation of SLC11A2 into extracellular vesicles (PubMed:27462458). More generally, plays a role in the extracellular transport of proteins between cells through the release in the extracellular space of microvesicles (PubMed:22315426). By participating in the ITCH-mediated ubiquitination and subsequent degradation of NOTCH1, negatively regulates the NOTCH signaling pathway (PubMed:23886940)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/Q8N5I2/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ARRDC1","classification":"Not Classified","n_dependent_lines":7,"n_total_lines":1208,"dependency_fraction":0.005794701986754967},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ARRDC1","total_profiled":1310},"omim":[{"mim_id":"619768","title":"ARRESTIN DOMAIN-CONTAINING PROTEIN 1; ARRDC1","url":"https://www.omim.org/entry/619768"},{"mim_id":"606409","title":"ITCHY E3 UBIQUITIN PROTEIN LIGASE; ITCH","url":"https://www.omim.org/entry/606409"},{"mim_id":"601387","title":"TUMOR SUSCEPTIBILITY GENE 101; TSG101","url":"https://www.omim.org/entry/601387"},{"mim_id":"190198","title":"NOTCH RECEPTOR 1; NOTCH1","url":"https://www.omim.org/entry/190198"},{"mim_id":"107941","title":"ARRESTIN, BETA, 2; ARRB2","url":"https://www.omim.org/entry/107941"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ARRDC1"},"hgnc":{"alias_symbol":["MGC40555"],"prev_symbol":[]},"alphafold":{"accession":"Q8N5I2","domains":[{"cath_id":"2.60.40.640","chopping":"5-133","consensus_level":"high","plddt":94.9287,"start":5,"end":133},{"cath_id":"2.60.40.640","chopping":"139-283","consensus_level":"high","plddt":94.4485,"start":139,"end":283}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8N5I2","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8N5I2-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8N5I2-F1-predicted_aligned_error_v6.png","plddt_mean":77.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ARRDC1","jax_strain_url":"https://www.jax.org/strain/search?query=ARRDC1"},"sequence":{"accession":"Q8N5I2","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8N5I2.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8N5I2/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8N5I2"}},"corpus_meta":[{"pmid":"30035390","id":"PMC_30035390","title":"Arrestin-Domain Containing Protein 1 (Arrdc1) Regulates the Protein Cargo and Release of Extracellular Vesicles.","date":"2018","source":"Proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/30035390","citation_count":57,"is_preprint":false},{"pmid":"23886940","id":"PMC_23886940","title":"Α-arrestin 1 (ARRDC1) and β-arrestins cooperate to mediate Notch degradation in mammals.","date":"2013","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/23886940","citation_count":48,"is_preprint":false},{"pmid":"29416926","id":"PMC_29416926","title":"ARRDC1 and ARRDC3 act as tumor suppressors in renal cell carcinoma by facilitating YAP1 degradation.","date":"2018","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29416926","citation_count":41,"is_preprint":false},{"pmid":"35300565","id":"PMC_35300565","title":"MicroRNA miR-124-3p suppresses proliferation and epithelial-mesenchymal transition of hepatocellular carcinoma via ARRDC1 (arrestin domain containing 1).","date":"2022","source":"Bioengineered","url":"https://pubmed.ncbi.nlm.nih.gov/35300565","citation_count":17,"is_preprint":false},{"pmid":"34499929","id":"PMC_34499929","title":"PAX5-activated lncRNA ARRDC1-AS1 accelerates the autophagy and progression of DLBCL through sponging miR-2355-5p to regulate ATG5.","date":"2021","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34499929","citation_count":15,"is_preprint":false},{"pmid":"33220929","id":"PMC_33220929","title":"Long noncoding RNA ARRDC1-AS1 is activated by STAT1 and exerts oncogenic properties by sponging miR-432-5p/PRMT5 axis in glioma.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/33220929","citation_count":11,"is_preprint":false},{"pmid":"38785998","id":"PMC_38785998","title":"Fusion with ARRDC1 or CD63: A Strategy to Enhance p53 Loading into Extracellular Vesicles for Tumor Suppression.","date":"2024","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/38785998","citation_count":8,"is_preprint":false},{"pmid":"36801666","id":"PMC_36801666","title":"Breast cancer stem cell-derived extracellular vesicles transfer ARRDC1-AS1 to promote breast carcinogenesis via a miR-4731-5p/AKT1 axis-dependent mechanism.","date":"2023","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36801666","citation_count":8,"is_preprint":false},{"pmid":"41392542","id":"PMC_41392542","title":"Targeted Intracellular Delivery via Precision Programming of ARRDC1-Mediated Microvesicles.","date":"2025","source":"Journal of extracellular vesicles","url":"https://pubmed.ncbi.nlm.nih.gov/41392542","citation_count":4,"is_preprint":false},{"pmid":"40025043","id":"PMC_40025043","title":"Scalable production and purification of engineered ARRDC1-mediated microvesicles in a HEK293 suspension cell system.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/40025043","citation_count":2,"is_preprint":false},{"pmid":"40824091","id":"PMC_40824091","title":"ARRDC1 inhibits the replication of Semliki Forest virus by regulating the ubiquitination and degradation of viral nsP4.","date":"2025","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/40824091","citation_count":1,"is_preprint":false},{"pmid":"42038593","id":"PMC_42038593","title":"Parallel Single-Tissue Summary-Data Mendelian Randomization and Functional Validation Identify the ARRDC1 Promoter SNP rs4494021 as a Genetic Marker Associated with Anxiety Disorders.","date":"2026","source":"Neuropsychiatric disease and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/42038593","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.09.24.614725","title":"Engineering Human ARMMs as Therapeutic Non-Viral Vehicles for  <i>in vivo</i>  Delivery of Genome Editing Payloads","date":"2024-09-26","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.24.614725","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":9024,"output_tokens":1704,"usd":0.026316,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":8542,"output_tokens":2483,"usd":0.052393,"stage2_stop_reason":"end_turn"},"total_usd":0.078709,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2013,\n      \"finding\": \"ARRDC1 (α-arrestin 1) heterodimerizes with β-arrestins and uses its PPxY motifs to directly bind the Itch E3 ubiquitin ligase, forming a tripartite complex that promotes Itch-mediated ubiquitylation and lysosomal degradation of non-activated Notch receptor; mutation of ARRDC1 PPxY motifs reduces Notch ubiquitylation and impairs lysosomal degradation.\",\n      \"method\": \"Co-immunoprecipitation, PPxY mutant transfection, ubiquitylation assays, lysosomal degradation assays in β-arrestin-/- and Itch-/- cells\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, mutagenesis of PPxY motifs, genetic validation in knockout cell lines, multiple orthogonal methods in one study\",\n      \"pmids\": [\"23886940\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ARRDC1 interacts with YAP1 via its PPXY motifs (binding the WW domains of YAP1) and facilitates Itch E3 ubiquitin ligase-mediated ubiquitination and proteasomal/lysosomal degradation of YAP1, thereby negatively regulating YAP1 protein stability and suppressing renal cell carcinoma cell growth, migration, invasion, and EMT.\",\n      \"method\": \"Tandem affinity purification/mass spectrometry, co-immunoprecipitation, lentiviral shRNA knockdown, functional cell assays (proliferation, migration, invasion, EMT)\",\n      \"journal\": \"American journal of cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, AP-MS interaction discovery, domain mapping (PPXY/WW), functional rescue with multiple orthogonal assays, single lab\",\n      \"pmids\": [\"29416926\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ARRDC1 regulates the release of both exosomes and ectosomes (extracellular vesicles) and controls their protein cargo; deletion of Arrdc1 in mouse embryonic fibroblasts alters EV protein composition, including enrichment of mitochondrial proteins in ectosomes and depletion of apoptotic cleavage/cornified envelope proteins in exosomes.\",\n      \"method\": \"Arrdc1-/- mouse embryonic fibroblasts, nanoparticle tracking analysis, proteomic analysis of isolated EVs\",\n      \"journal\": \"Proteomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with quantitative EV analysis and proteomics, single lab, two orthogonal methods\",\n      \"pmids\": [\"30035390\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ARRDC1 restricts Semliki Forest virus (alphavirus) replication by binding to viral nonstructural protein 4 (nsP4) and facilitating its ubiquitination-dependent degradation; this antiviral function requires ARRDC1's plasma membrane localization and its ubiquitin ligase binding motif (PPxY).\",\n      \"method\": \"siRNA knockdown, CRISPR/Cas9 knockout, trans-complementation, Co-immunoprecipitation (ARRDC1–nsP4 interaction), viral replication assays, PPxY motif mutant analysis\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO/KD plus trans-complementation, Co-IP of viral substrate, domain/motif mutant validation, multiple orthogonal methods in one study\",\n      \"pmids\": [\"40824091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Fusion of ARRDC1 to p53 (ARRDC1-p53) substantially increases loading of p53 fusion protein and its mRNA into small extracellular vesicles (sEVs), demonstrating that ARRDC1 serves as an active cargo-loading mechanism for sEV biogenesis; overexpression of ARRDC1 also boosts sEV production (elevated TSG101 and LAMP1).\",\n      \"method\": \"Overexpression of ARRDC1-p53 fusion constructs in HEK293T, Western blot for sEV markers, functional apoptosis/proliferation assays in recipient cells\",\n      \"journal\": \"Biomolecules\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — overexpression fusion strategy with functional readout, multiple cell assays, single lab\",\n      \"pmids\": [\"38785998\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Engineered ARRDC1-mediated microvesicles (ARMMs) can be loaded with protein, mRNA, or CRISPR-Cas9 cargo and deliver them intracellularly; surface decoration with cell-targeting ligands enables selective delivery to CD8+ T cells or parvalbumin-positive neurons in vivo, demonstrating that ARRDC1's membrane budding activity can be harnessed for programmable intracellular cargo delivery.\",\n      \"method\": \"Engineered ARMM production with targeted surface proteins, in vitro and in vivo delivery assays, functional gene editing readouts\",\n      \"journal\": \"Journal of extracellular vesicles\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo functional delivery with multiple cargo types, single lab, engineering study rather than pure mechanistic dissection\",\n      \"pmids\": [\"41392542\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ARRDC1 is a plasma membrane-localized α-arrestin adaptor protein that uses its PPxY motifs to recruit the Itch E3 ubiquitin ligase and cooperates with β-arrestins to drive ubiquitination and lysosomal/proteasomal degradation of substrates including Notch and YAP1; it also controls the biogenesis and protein cargo of extracellular vesicles (both exosomes and ectosomes), and its ubiquitin ligase-binding activity and membrane localization enable an antiviral function through ubiquitin-mediated degradation of alphavirus nsP4.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ARRDC1 is a plasma membrane α-arrestin adaptor that couples substrate recognition to ubiquitin-mediated turnover and drives the budding of extracellular vesicles [#0, #2]. It heterodimerizes with β-arrestins and uses its PPxY motifs to directly recruit the Itch E3 ubiquitin ligase, forming a tripartite complex that ubiquitylates substrates and routes them to lysosomal/proteasomal degradation; mutation of the PPxY motifs abolishes this activity [#0]. Through this PPxY/Itch axis it promotes degradation of non-activated Notch [#0] and binds the WW domains of YAP1 to control YAP1 protein stability, with loss of ARRDC1-driven YAP1 turnover relieving suppression of renal cell carcinoma growth, migration, invasion, and EMT [#1]. Independently of its degradative role, ARRDC1 governs the biogenesis and protein cargo of both exosomes and ectosomes, and its membrane-budding activity can be redirected to actively load defined protein and nucleic-acid cargo into secreted vesicles [#2, #4, #5]. The same membrane localization and ubiquitin-ligase-binding motif underlie an antiviral function: ARRDC1 binds alphavirus nonstructural protein nsP4 and promotes its ubiquitination-dependent degradation to restrict Semliki Forest virus replication [#3].\",\n  \"teleology\": [\n    {\n      \"year\": 2013,\n      \"claim\": \"Established the core molecular logic of ARRDC1 as an adaptor: how could an α-arrestin direct substrate degradation? It bridges β-arrestins and the Itch E3 ligase via PPxY motifs to ubiquitylate and degrade Notch.\",\n      \"evidence\": \"Co-IP, PPxY mutant transfection, ubiquitylation and lysosomal degradation assays in β-arrestin-/- and Itch-/- cells\",\n      \"pmids\": [\"23886940\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Notch is recognized directly by ARRDC1 or via β-arrestin is not resolved\", \"Physiological contexts of Notch regulation by ARRDC1 not defined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Extended the adaptor model to a second substrate and a disease context: ARRDC1 binds YAP1 WW domains through its PPXY motifs and drives Itch-mediated YAP1 degradation, positioning ARRDC1 as a tumor suppressor in renal cell carcinoma.\",\n      \"evidence\": \"AP-MS, reciprocal Co-IP, PPXY/WW domain mapping, shRNA knockdown, proliferation/migration/invasion/EMT assays\",\n      \"pmids\": [\"29416926\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo tumor evidence not established\", \"Relative contribution of proteasomal vs lysosomal degradation unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined a degradation-independent role: how does ARRDC1 shape extracellular vesicle output? Genetic loss alters the protein cargo of both exosomes and ectosomes.\",\n      \"evidence\": \"Arrdc1-/- MEFs, nanoparticle tracking, proteomic profiling of isolated EVs\",\n      \"pmids\": [\"30035390\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which ARRDC1 selects specific cargo classes not defined\", \"Single cell type (MEF), not confirmed across tissues\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstrated that ARRDC1 actively loads cargo into vesicles rather than passively associating: ARRDC1-p53 fusion enriches p53 protein and mRNA in small EVs and boosts sEV production.\",\n      \"evidence\": \"ARRDC1-p53 fusion overexpression in HEK293T, sEV marker Western blots, functional assays in recipient cells\",\n      \"pmids\": [\"38785998\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Overexpression/fusion strategy may not reflect endogenous cargo loading\", \"Mechanism of mRNA recruitment unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Showed ARRDC1's budding activity is engineerable: ARRDC1-mediated microvesicles carrying protein, mRNA, or CRISPR-Cas9 can be surface-targeted for selective in vivo delivery.\",\n      \"evidence\": \"Engineered ARMMs with targeting ligands, in vitro and in vivo delivery and gene-editing readouts\",\n      \"pmids\": [\"41392542\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Engineering proof-of-concept rather than endogenous mechanism\", \"Endogenous physiological cargo and triggers of budding not addressed\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Connected ARRDC1's degradative adaptor function to host defense: it binds alphavirus nsP4 and promotes its ubiquitination-dependent degradation to restrict viral replication, requiring membrane localization and the PPxY motif.\",\n      \"evidence\": \"siRNA knockdown, CRISPR/Cas9 KO, trans-complementation, ARRDC1–nsP4 Co-IP, PPxY mutant analysis, viral replication assays\",\n      \"pmids\": [\"40824091\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the same Itch ligase mediates nsP4 ubiquitination not shown\", \"Breadth of antiviral activity against other viruses not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ARRDC1 selects its diverse substrates and EV cargo, and whether its degradative and vesicle-budding functions are mechanistically linked, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of ARRDC1 substrate or cargo recognition\", \"Determinants distinguishing degradative targeting from EV cargo loading unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 1, 3]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [2, 4, 5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [2, 4, 5]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 1, 3]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ITCH\", \"Notch\", \"YAP1\", \"nsP4\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}